Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bi-ventricular assist

This article was originally published in The Gray Sheet

Executive Summary

Biophan Technologies will direct the development, regulatory approval and marketing of Myotech's Myo-Vad minimally invasive bi-ventricular assist device. Myo-Vad is based on Myotech's Direct Mechanical Ventricular Assist (DMVA) technology - a flexible polymer cup installed around the heart through a small incision in about three minutes. The cup, featuring a pneumatically activated liner connected to a control line, compresses and expands to support both ventricles of the heart. The technology has been tested in over 700 animals...

You may also be interested in...

Biophan, Siemens sign pact

Development and commercialization of magnetic resonance imaging technologies is the goal of a new research collaboration inked between Biophan Europe and Siemens' MRI division. The deal follows Biophan's successful development of an MRI system to visualize implanted medical devices, such as heart valves, and Siemens' unveiling of a new MRI scanning technology, the 1.5 T wide-aperture Magnetrom Espree (1"The Gray Sheet" Sept. 19, 2005, In Brief)...

Recent eMDR Change By FDA Asks Adverse Event Reporters About Third-Party Servicers

The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.

Experts: HHS Review Proposal May Free Industry From Regulatory Red Tape

Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts